Equities
  • Price (EUR)88.84
  • Today's Change2.67 / 3.10%
  • Shares traded2.04k
  • 1 Year change-8.88%
  • Beta0.6792
Data delayed at least 15 minutes, as of Sep 25 2020 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

  • Revenue in USD (TTM)27.93bn
  • Net income in USD4.38bn
  • Incorporated2014
  • Employees90.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MDT:NYQ since
announced
Transaction
value
Companion Medical IncAnnounced11 Aug 202011 Aug 2020Announced2.77%--
Digital Surgery LtdDeal completed13 Feb 202013 Feb 2020Deal completed-11.44%--
Stimgenics LLCDeal completed08 Jan 202008 Jan 2020Deal completed-9.90%--
Klue Labs IncDeal completed17 Dec 201917 Dec 2019Deal completed-9.94%--
Data delayed at least 15 minutes, as of Sep 25 2020 21:10 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.